BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping BioLineRx Ltd. announces its Q3 2025 financial results, alongside an update on corporate initiatives, including joint venture developments.

BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping #Israel #Tel_Aviv #BioLineRx #motixafortide #GLIX1

BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting BioLineRx Ltd. reveals promising data from its combination therapy trial for pancreatic cancer, showcasing a significant advance in treatment options for this challenging disease.

BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting #Israel #Tel_Aviv #BioLineRx #pancreatic_cancer #motixafortide

BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments BioLineRx has reported its Q1 2025 financial results, showcasing significant advancements in drug development and corporate strategies in oncology and rare diseases.

BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments #Israel #Tel_Aviv #BioLineRx #APHEXDA #motixafortide